Knotková V, Nĕmecek K, Tarayeva I E, Krasnova T N
II. interní klinika 1. LF UK, Praha.
Vnitr Lek. 1993 Dec;39(12):1157-63.
The authors present their long standing experience with immunosuppressive treatment of patients with nephrotic syndrome associated with primary chronic membranous, mesangioproliferative and mesangiocapillary glomerulonephritis. Of a total of 127 patients 99 were treated with prednisone and cyclophosphamide and 28 with cyclophosphamide only. Clinical remission developed in 89 patients (70%). Remissions developed independently on morphological findings and initial proteinuria, but more frequently in patients with a still normal glomerular filtration. In combined immunosuppression 77% of the treated patients developed remission, while only 48% treated with cyclophosphamide alone. 88% of the patients survive an average period of 10 years. From the investigation it is apparent that long-term and early combined immunosuppression has a favourable impact on the course of primary chronic glomerulonephritis with nephrotic syndrome.
作者介绍了他们在对原发性慢性膜性、系膜增生性和系膜毛细血管性肾小球肾炎相关肾病综合征患者进行免疫抑制治疗方面的长期经验。在总共127例患者中，99例接受了泼尼松和环磷酰胺治疗，28例仅接受环磷酰胺治疗。89例患者（70%）实现了临床缓解。缓解情况与形态学结果和初始蛋白尿无关，但在肾小球滤过仍正常的患者中更常见。在联合免疫抑制治疗中，77%的治疗患者实现了缓解，而仅接受环磷酰胺治疗的患者中这一比例为48%。88%的患者存活了平均10年。从该研究中可以明显看出，长期和早期联合免疫抑制对原发性慢性肾小球肾炎伴肾病综合征的病程有积极影响。
